Abstract
We compare the dosimetrical differences between plans generated for helical tomotherapy by using the 2D or 3D the margining technique for the treatment of prostate cancer. Ten prostate cancer patients were included in this study. For 2D plans, the planning target volume (PTV) was created by adding 5 mm (lateral/anterior-posterior) to the clinical target volume (CTV). For 3D plans, a 5-mm margin was added not only lateral/anterior-posterior, but also superior-inferior, to the CTV. Various dosimetrical indices, including the prescription isodose to target volume (PITV) ratio, conformity index (CI), homogeneity index (HI), target coverage index (TCI), modified dose homogeneity index (MHI), conformation number (CN), critical organ scoring index (COSI), and quality factor (QF) were determined to compare the different treatment plans. Differences between the 2D and the 3D PTV indices were not significant except for the CI (p = 0.023). 3D margin plans (11195 MUs) resulted in higher (13.0%) monitor units than 2D margin plans (9728 MUs). There were no significant differences in any organs at risk (OARs) between the 2D and the 3D plans. Overall, the average dose for the 2D plan was slightly lower than that for the 3D plan dose. Compared to the 2D plan, the 3D plan increased the average treatment time by 1.5 minutes; however, this difference was not statistically significant (p = 0.082). We confirmed that the 2D and the 3D margin plans were not significantly different with regard to various dosimetric indices such as the PITV, CI, and HI for PTV and the OARs with tomotherapy.
Similar content being viewed by others
References
A. Jemal, A. Thomas, T. Murray and M. Thun, CA Cancer J. Clin. 52, 23 (2002).
G. A. Viani, L. G. da Silva and E. J. Stefano, Int. J. Radiat. Oncol. Biol. Phys. 83, e619 (2012).
M. C. Aznar et al., Radiother. Oncol. 97, 480 (2010).
Intensity Modulated Radiation Therapy Collaborative Working Group, Int. J. Radiat. Oncol. Biol. Phys. 51, 88 (2001).
N. Hardcastle, A. Davies, K. Foo, A. Miller and P. E. Metcalfe, J. Med. Imaging. Radiat. Oncol. 54, 235 (2010).
S. Ladjevardi, A. Berglund, E. Varenhorst, O. Bratt, A. Widmark, and G. Sandblom, BJU. Int. 111, 381 (2012).
J. Balog and E. Soisson, Int. J. Radiat. Oncol. Biol. Phys. 71, S113 (2008).
T. R. Mackie, Phys. Med. Biol. 51, R427 (2006).
S. Malone et al., Int. J. Radiat. Oncol. Biol. Phys. 84, 725 (2012).
T. E. Byrne, Med. Dosim. 30, 155 (2005).
K. M. Langen et al., Int. J. Radiat. Oncol. Biol. Phys. 62, 1517 (2005).
C. Beltran, M. G. Herman and B. J. Davis, Int. J. Radiat. Oncol. Biol. Phys. 70, 289 (2008).
A. Kaiser et al., Int. J. Radiat. Oncol. Biol. Phys. 66, 949 (2006).
D. J. Little, L. Dong, L. B. Levy, A. Chandra and D. A. Kuban, Int. J. Radiat. Oncol. Biol. Phys. 56, 1218 (2003).
F. Trichter and R. D. Ennis, Int. J. Radiat. Oncol. Biol. Phys. 56, 1225 (2003).
M. Palombarini, S. Mengoli, P. Fantazzini, C. Cadioli, C. Degli Esposti and G. P. Frezza, Radiat. Oncol. 7, 56 (2012).
L. Santanam et al., Int. J. Radiat. Oncol. Biol. Phys. 71, 1511 (2008).
P. M. van Haaren, A. Bel, P. Hofman, M. van Vulpen, A. N. Kotte and U. A. van der Heide, Radiother. Oncol. 90, 291 (2009).
J. Zhou et al., Med. Dosim. 35, 31 (2010).
J. L. Bedford and G. S. Shentall, Med. Phys. 25, 224 (1998).
R. Belshi, D. Pontvert, J. C. Rosenwald and G. Gaboriaud, Int. J. Radiat. Oncol. Biol. Phys. 37, 689 (1997).
J. C. Stroom and P. R. Storchi, Phys. Med. Biol. 42, 745 (1997).
C. H. Ketting, M. Austin-Seymour, I. Kalet, J. Unger, S. Hummel and J. Jacky, Int. J. Radiat. Oncol. Biol. Phys. 445 (1997).
V. S. Khoo, J. L. Bedford, S. Webb and D. P. Dearnaley, Int. J. Radiat. Oncol. Biol. Phys. 42, 673 (1998).
A. M. Pooler, H. M. Mayles, O. F. Naismith, J. P. Sage and D. P. Dearnaley, Radiother. Oncol. 86, 43 (2008).
D. W. Smith, A. M. Morgan, A. M. Pooler and D. I. Thwaites, Br. J. Radiol. 81, 406 (2008).
B. Emami et al., Int. J. Radiat. Oncol. Biol. Phys. 21, 109 (1991).
S. M. Bentzen et al., Int. J. Radiat. Oncol. Biol. Phys. 76, S3 (2010).
C. A. Lawton et al., Int. J. Radiat. Oncol. Biol. Phys. 74, 383 (2009).
E. Shaw et al., Int. J. Radiat. Oncol. Biol. Phys. 27, 1231 (1993).
T. Knoos, I. Kristensen and P. Nilsson, Int. J. Radiat. Oncol. Biol. Phys. 42, 1169 (1998).
M. Yoon et al., J. Appl. Clin. Med. Phys. 8, 9 (2007).
A. van’t Riet, A. C. Mak, M. A. Moerland, L. H. Elders and W. van der Zee, Int. J. Radiat. Oncol. Biol. Phys. 37, 731 (1997).
J. Menhel, D. Levin, D. Alezra, Z. Symon and R. Pfeffer, Phys. Med. Biol. 51, 5363 (2006).
A. Pyakuryal, W. K. Myint, M. Gopalakrishnan, S. Jang, J. A. Logemann and B. B. Mittal, J. Appl. Clin. Med. Phys. 11, 3013 (2010).
ICRU, J. ICRU. 10, Np (2010).
J. Yang, A. S. Garden, Y. Zhang, L. Zhang and L. Dong, Med. Phys. 39, 5136 (2012).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cao, Y.J., Lee, S., Chang, K.H. et al. Optimized planning target volume margin in helical tomotherapy for prostate cancer: Is there a preferred method?. Journal of the Korean Physical Society 67, 26–32 (2015). https://doi.org/10.3938/jkps.67.26
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.3938/jkps.67.26